With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

While an investment in Neurocrine remains dependent on INGREZZA, the company has also received FDA approval for its new drug, CRENESSITY (crinecerfont) as of December. CRENESSITY is a treatment ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market ...

Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

While announcing billions of dollars in new U.S. investments, company chief David Ricks called for an extension of 2017 tax ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch ? First of three planned Phase 3 azetukalner MDD studies ...

The non-GAAP net income was $173.4 million, showing improved margins due to strong sales in its drug portfolio. Neurocrine's R&D expenses increased by 35% to $185.6 million, highlighting its ...